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Most pathogens infect through mucosal surfaces, and parenteral immunization typically 
fails to induce effective immune responses at these sites. Development of oral-ad-
ministered vaccines capable of inducing mucosal as well as systemic immunity while 
bypassing the issues of antigen degradation and immune tolerance could be crucial 
for the control of enteropathogens. This study demonstrates that U-Omp19, a bacterial 
protease inhibitor with immunostimulatory features, coadministered with Salmonella 
antigens by the oral route, enhances mucosal and systemic immune responses in mice. 
U-Omp19 was able to increase antigen-specific production of IFN-γ and IL-17 and 
mucosal (IgA) antibody response. Finally, oral vaccination with U-Omp19 plus Salmonella 
antigens conferred protection against virulent challenge with Salmonella Typhimurium, 
with a significant reduction in bacterial loads. These findings prove the efficacy of this 
novel adjuvant in the Salmonella infection model and support the potential of U-Omp19 
as a suitable adjuvant in oral vaccine formulations against mucosal pathogens requiring 
T helper (Th)1–Th17 protective immune responses.
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inTrODUcTiOn
It is generally accepted that vaccination is the most efficient and cost-effective form of preventing 
infectious diseases. Although most vaccines currently licensed are administered by parenteral route, 
this vaccination strategy usually fails to elicit adequate mucosal immune responses. As a result, dis-
eases caused by mucosal pathogens are still among the major causes of death in developing countries. 
It is well documented that oral immunization is capable of generating strong protective immunity 
at the intestinal mucosa as well as systemically (1–5). However, oral administration of antigens faces 
two major issues, one being degradation of the antigen by enzymes present at the gastrointestinal 
tract and the other being the induction of immune tolerance against the administered antigen (6–8). 
Current oral vaccines based on attenuated pathogens are usually capable of bypassing these difficul-
ties but, on the other hand, present important safety concerns (9). The safe alternative consists on the 
development of oral killed or subunit vaccines, but this holds major challenges since they are poorly 
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immunogenic and usually require multiple doses and the use of 
an effective oral adjuvant (10, 11).
Two bacterial products are being used as oral adjuvants in the 
mouse model, cholera toxin (CT) from Vibrio cholerae and heat-
labile enterotoxin (LT) from Escherichia coli (12). Since entero-
toxicity seriously limits the practical use of these compounds in 
humans, modifications have been generated to reduce this effect. 
A modified version of CT lacking the A subunit (CTB) is now 
currently licensed as part of the Dukoral® vaccine for human use 
(13) and also a double mutant of LT, which retains its adjuvant 
properties is under clinical trial (14). However, neither of these 
molecules is capable of overcoming antigen degradation in the 
gastrointestinal tract. Interesting strategies to address this issue 
include antigen delivery through intestine-targeted pH-depend-
ent microparticles (15), biodegradable nano or microparticles 
(16–18), and antigen targeting to M cells (19). However, there 
is still a need for an appropriate oral adjuvant, especially one 
that induces T helper (Th)1 and CD8+ T cell immune responses 
required for protective immunity against intracellular pathogens.
In previous work we have studied the unlipidated form of a 
bacterial protease inhibitor from Brucella abortus, U-Omp19, 
as an oral adjuvant. We have demonstrated that it has self-
adjuvanting properties (20) and can also enhance immune 
responses against the model antigen chicken ovalbumin (OVA) 
(21, 22). The mechanisms responsible for the adjuvant activity of 
U-Omp19 rely in the inhibition of stomach and gut proteases and 
recruitment of immune cells to the gastrointestinal mucosa (21) 
as well as increased maturation of DCs and enhanced presenta-
tion of the antigen by means of delaying antigen digestion at the 
lysosomes (23). Thus, mucosal as well as systemic OVA-specific 
immune responses, Th1, and CD8+ are enhanced if U-Omp19 is 
codelivered orally.
We now focused on assessing U-Omp19’s capacity to increase 
immune response against antigens from an enteric pathogen 
that invades the host through the gastrointestinal mucosa. 
The enterobacteria Salmonella infect humans and animals and 
depending on the serotype can cause disease of different sever-
ity (24). S. Typhi invades the gut mucosa and is drained trough 
the lymphatic system into lymph nodes, spleen, and liver (25). 
The main structural protein of Salmonella flagellum is Flagellin 
(FliC). Flagellin was demonstrated to play an important role in 
the protection against Salmonella challenge (26). Also, a sig-
nificant fraction of Salmonella-specific CD4+ T cells respond to 
FliC, and this antigen has the capacity to protect naive mice from 
lethal Salmonella infection (27). Another protein expressed and 
secreted by Salmonella is SseB, which promotes membrane pore 
formation, allowing proteins to access host cytoplasm. SseB was 
highlighted in a proteomic screen and has been shown to protect 
mice against Salmonella infection (28). Th1 immunity involv-
ing IFN-γ is strongly associated with the protective immune 
response to Salmonella (29–31). The natural route of infection 
and the need for a Th1-biased response, along with the current 
emergence of multidrug-resistant strains, makes this pathogen 
a strong candidate for oral vaccination with the novel adjuvant 
U-Omp19. The conventional mouse model for the study of this 
disease is infection of susceptible mouse strains with Salmonella 
enterica serovar Typhimurium (S. Typhimurium) that causes 
an invasive systemic disease that is similar in many respects to 
typhoid fever (30–32). Therefore, in this work U-Omp19 was 
studied in vivo for its ability to elicit mucosal and systemic immu-
nity against coadministered antigens from S. Typhimurium. 
We assessed a killed-vaccine immunization alternative, using a 
heat-killed extract of S. Typhimurium (HKS) as well as a proof 
of concept using FliC and SseB antigens in a potential subunit 
vaccine alternative.
MaTerials anD MeThODs
ethics statement
All experimental protocols of this study were conducted in 
agreement with international ethical standards for animal 
experimentation (Helsinki Declaration and its amendments, 
Amsterdam Protocol of welfare, and animal protection and 
National Institutes of Health, USA, guidelines: Guide for the Care 
and Use of Laboratory Animals). The protocols of this study were 
approved by the Institutional Committee for the Care and Use 
of Experimentation Animals from the University of San Martin 
(UNSAM) or from University of California Davis.
Mice
BALB/c and CF-1 mice were obtained from Animal Facility 
at IIB-UNSAM or from Jackson Laboratory and were used at 
6–12 weeks of age. Mice were housed in appropriate conventional 
animal care facilities and handled according to international 
guidelines required for animal experiments at IIB-UNSAM or at 
University of California Davis.
antigens and adjuvants
The recombinant unlipidated (U-) Omp19 was expressed and 
purified as previously described (33). Lipopolysaccharide (LPS) 
contamination was adsorbed with Sepharose-polymyxin B 
(SIGMA, St. Louis, MO, USA). Endotoxin and protein concentra-
tion were determined as in Ref. (21). All U-Omp19 preparations 
used contained <0.10 endotoxin U/mg of protein. CT and CT 
subunit B (CTB) from V. cholerae were purchased from SIGMA, 
St. Louis, MO, USA.
For preparation of heat-killed extract of Salmonella 
Typhimurium (HKS), AroA S. Typhimurium (streptomycin 
resistant) was plated in LB agar with 10 µg/ml of streptomycin and 
grown overnight at 37°C. Afterward, eight isolated colonies were 
taken from the LB plate and grown in LB medium with 10 µg/
ml of streptomycin at 37°C with agitation of 130 rpm overnight. 
The next morning, the culture was diluted 1 in 25 in LB medium 
with 10 µg/ml of streptomycin and grown until reaching an OD 
600 nm of 0.85 (≈1 × 109 CFU/ml), for the bacterial culture to 
be in growth phase. After centrifugation for 10 min at 6,000 rpm 
at 4°C, supernatant was discarded and bacterial pellet was sus-
pended in sterile PBS. This bacterial extract was then heated at 
63°C for 3 h; afterward it was heated at 100°C for 10 min and 
finally sonicated for 10 min in an ice-cold environment. Protein 
concentration was determined by the bicinchroninic acid assay 
(Pierce, Rockford, IL, USA) and aliquots of 1–5 × 106 CFU/μg of 
extract were stored at −70°C until used.
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SseB was obtained as described in Ref. (28). Flagellin was puri-
fied from LPS-deficient S. Typhimurium X4700 as in Ref. (34).
antigen Degradation studies
To obtain the mouse stomach extract, five mice were fasted over-
night. Stomach was obtained from every mouse and mechani-
cally homogenized in 500  µl of ice-cold PBS (Ultra-Turrax 
homogenizer, IKA). Homogenates were pooled, immediately 
centrifuged 15  min at 6,000  rpm, and supernatants were used 
as mouse stomach extract. Standardization of extracts was done 
by measuring (i) total protein content by the bicinchroninic acid 
assay (Pierce, Rockford, IL, USA) and (ii) protease activity of the 
extract. Protease activity was determined using a casein fluori-
metric kit (EnzChek, Invitrogen, Carlsbad, CA, USA). EnzChek 
kit contains casein BODIPY FL, a protein in which fluorescence 
is quenched. Protease-catalyzed hydrolysis releases this quench-
ing, yielding bright green fluorescent peptides. The increase in 
fluorescence is proportional to protease activity.
To examine whether U-Omp19 would limit digestion of HKS 
by stomach proteases, HKS was incubated with stomach extracts 
with or without U-Omp19 for 5 h. Following incubation, each 
mixture of reaction was separated on 12% SDS-PAGE. To increase 
sensitivity of this assay we performed Western Blot against FliC 
(Salmonella Flagellum Protein-FliC-) an antigen that has shown 
to be protective in mice (26, 27). Membrane was incubated over-
night with anti-FliC IgG MAb (Invivogen Carlsbad, CA, USA), 
followed by 1-h incubation with anti-IgG-HRP (SIGMA, St. 
Louis, MO, USA), and reveled using ECL kit (Pierce, Rockford, 
IL, USA). This helped us determine if U-Omp19 can protect 
digestion of this particular protein in the heat-killed preparation 
of Salmonella.
immunization
BALB/c and CF-1 mice were immunized orally—intragastrically 
by oral gavage—with HKS (100  µg ≈  1–5 ×  108  CFU) alone, 
with U-Omp19 (200 µg), with CTB or with CT (10 µg) on days 
0 and 7. These were diluted in PBS until a final volume of 200 µl 
per administration per mouse. Dose of U-Omp19 was chosen 
considering previous studies on protease inhibitory capacity of 
U-Omp19 in vivo (21), whereas CT dose was selected for being 
the typical effective oral dose described in the literature (35–38). 
Mice were fasted 2  h before and after immunization. Fifteen 
minutes before oral immunization, mice were administered with 
100 µl of 0.1M sodium bicarbonate.
For subunit vaccine experiments, BALB/c mice were intrave-
nously or orally immunized on days 0 and 30 with (i) buffer, (ii) 
20 µg SseB + 20 µg Flagellin + 80 µg U-Omp19, or (iii) 20 µg 
SseB + 20 µg Flagellin + 10 µg monophosphoryl lipid A (MPLA) 
(Invivogen, Carlsbad, CA, USA) as a control adjuvant.
Determination of Th immune responses
Spleen and MLNs’ single cell suspensions from immunized mice 
were obtained as in Ref. (21) 14 days post-last immunization 
and cells’ suspensions were cultured in the presence of 0.5 or 
10 micrograms/ml of HKS or complete medium. After 3 days, 
cell culture supernatants were collected and IFN-γ, IL-4, IL-10, 
and IL-17 were determined by ELISA (Pharmingen, San Diego, 
CA, USA).
Delayed Type hypersensitivity assay (DTh) 
Test
Two weeks after the last immunization, mice were injected 
intradermally in one footpad with 20  µg of HKS in 40  µl of 
saline and in the contralateral footpad with an equal volume of 
saline. Footpad thickness was measured 72 h later using a digital 
caliper with a precision of 0.01 mm, and the mean increase in 
footpad thickness (mm) was calculated as (footpad thickness) 
HKS − (footpad thickness) saline.
Determination of iga in Feces and igg in 
sera
Two weeks after the last immunization, fecal extracts were pre-
pared as in Ref. (20) and used on the same day. Mice were bled via 
the cheek pouch on the submandibular vein. Blood was allowed 
to clot, and serum was removed and stored at −20°C until used.
For ELISA, HKS extract was diluted to 1 mg/ml in NaHCO3 1M 
pH 9.6, and ELISA plates were coated with 100 µg/well overnight 
at 4°C. Plates were blocked with bovine serum albumin 2% in PBS 
at 37°C for 1 h and washed with PBS-Tween 0.05%. Samples were 
incubated for 2 h at room temperature and after washing, anti-
mouse IgA-HRP (Abcam, Cambridge, MA, USA) or anti-mouse 
IgG-HRP (SIGMA, St. Louis, MO, USA) diluted in PBS–BSA 1% 
were added for 1 h at room temperature. Finally, detection was 
performed with BD OptEIA™ TMB Substrate Reagent Set (BD, 
San Diego, CA, USA). Anti-U-Omp19 ELISA was performed as 
previously described (33).
Protection experiments
HKS Experiments
For BALB/c mice, 14 days post-last immunization, mice from each 
group were challenged intragastrically with 0.5–1 × 105 CFU of 
virulent S. Typhimurium. For CF-1 mice, 21 days post-last immu-
nization, mice from each group were challenged intragastrically 
with 1–5 × 105 CFU of virulent S. Typhimurium. Mice were fasted 
for 6  h before and 1  h after infection. Fifteen minutes before 
infection mice were administered intragastrically with 100 µl of 
NaHCO3 0.1M pH8. Sacrifice was performed 6 days postinfection 
for BALB/c mice and 40 days postinfection for CF-1 mice. Spleens 
and livers were obtained and homogenized in sterile PBS. Serial 
dilutions of the homogenates were plated on SS agar plates and 
incubated overnight at 37°C to determine bacterial colonization.
Recombinant Antigens Experiments
Thirty days post-last immunization, mice were intravenously 
(tail vein) infected with 1,000 CFU of virulent Salmonella SL1344 
strain. Four days later spleen and liver were obtained, and bacte-
rial load was determined by homogenization, serial dilution, and 
plating on MacConkey agar plates.
statistical analysis
Statistical analysis and plotting were performed using GraphPad 
Prism 5 software. Data (with logarithmic transformation when 
FigUre 1 | U-Omp19 induces an increase in fecal iga antibodies against hKs. BALB/c mice were orally immunized on days 0 and 7 with buffer, HKS alone, 
or HKS + U-Omp19. Fourteen days post-last immunization, sera and feces were collected. HKS-specific IgG in serum (a), HKS-specific IgA in fecal extracts (B), 
and U-Omp19-specific IgA in fecal extracts (c) were detected by ELISA. Individual mice are shown as scatter dots (*p < 0.05; ANOVA plus Bonferroni’s multiple 
comparisons test).
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necessary) were tested for normality and homoscedasticity before 
using parametric statistics (one-way ANOVA) or analyzed using 
non-parametric statistics (Kruskal–Wallis). Data were tested for 
normality using the Kolmogorov–Smirnov test, and for equal 
variance, using the Levene Median test. Results shown are repre-
sentative of at least two independent experiments. Results were 
expressed as mean ± SEM. Significance level was set at p < 0.05.
resUlTs
U-Omp19 Protects hKs antigens from 
stomach Digestion
Previous studies have shown that U-Omp19 has inhibitory activ-
ity over several proteases at the digestive tract, particularly pepsin, 
the main protease present at the stomach (21). Thus, U-Omp19’s 
activity in an in  vitro degradation assay incubating HKS with 
mouse stomach extract was evaluated. One of the antigens present 
in the HKS extract is FliC. FliC is a major protein and virulence 
factor from Salmonella that has the capacity to protect naive mice 
from lethal Salmonella infection (26–28), so if degradation of FliC 
by stomach enzymes is reduced, more FliC can reach inductive 
sites and thus it is likely to be able to perform as a protective anti-
gen in an oral vaccine. Detection of FliC by western blot confirms 
that U-Omp19 protects antigen from degradation by stomach 
enzymes in vitro (Figure S1 in Supplementary Material), which 
may contribute to the induction of a stronger immune response.
Vaccination with hKs Plus U-Omp19 
induces an increase in Mucosal antibody 
response
There is evidence that antibodies are associated with protec-
tion against S. Typhimurium (39, 40). To assess U-Omp19’s 
adjuvant effect on the antibody response against HKS antigens, 
HKS-specific antibody production in orally immunized mice 
was examined. Intestinal HKS-specific IgA antibodies were 
significantly elevated in fecal pellets from mice immunized 
with HKS plus U-Omp19 compared to those immunized with 
HKS alone. Serum HKS-specific IgG levels, on the other hand, 
were not altered if U-Omp19 was coadministered with HKS. Of 
note, immunization with U-Omp19 as adjuvant did not induce a 
mucosal antibody response against itself (Figure 1).
U-Omp19 induces systemic and Mucosal 
cellular immune responses against 
coadministered hKs antigens
Since the cellular immune response has been reported to be 
important for protection against Salmonella (41–43), the capac-
ity of U-Omp19 to increase HKS-specific cell-mediated immune 
response in a DTH assay was tested in immunized mice. After 
72  h of intradermal administration of HKS, mice that had 
been previously delivered with HKS + U-Omp19 displayed an 
increased DTH response compared to the HKS-immunized 
group (Figure  2A). The profile of cytokine production upon 
antigen stimulation was studied after intragastric immunization 
with HKS, HKS + U-Omp19, or HKS + CT as mucosal adjuvant 
control. Splenocytes from HKS +  U-Omp19 immunized mice 
presented a significant increase in IFN-γ and IL-17 production 
upon HKS stimulation in  vitro in comparison to HKS alone 
immunization. In contrast, HKS stimulation in  vitro did not 
increase IL-4 or IL-10 production (Figure  2B). CT induced 
a statistically significant increase in IL-17 and a slight but not 
significant increase in IFN-γ.
To evaluate U-Omp19’s effect on HKS-specific mucosal 
immune response, MLNs from immunized mice were obtained 
and stimulated in vitro with HKS. As seen in splenocytes, IFN-γ 
and IL-17 levels in supernatants from MLNs’ cells were increased 
in animals immunized with HKS + U-Omp19 compared to HKS 
alone (Figure 2C). Production of IL-4 and IL-10 did not differ 
between groups (data not shown).
coadministration of hKs with U-Omp19 
reduces Bacterial Burden after Oral 
challenge with S. Typhimurium
To evaluate if the induction of an adaptive immune response by 
HKS + U-Omp19 would lead to an increased level of protection 
against infection, immunized mice were orally infected with 
FigUre 2 | continued
5
Risso et al. Omp19’s Adjuvanticity in Anti-Salmonella Vaccine
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 171
FigUre 3 | immunization with U-Omp19 + hKs reduces bacterial 
burden after Salmonella infection. (a,B) BALB/c mice were orally 
immunized on days 0 and 7 with HKS alone, HKS + U-Omp19, or 
HKS + CTB. Fourteen days post-last immunization, mice were orally infected 
with Salmonella Typhimurium. Six days postinfection mice were sacrificed, 
spleen (a) and liver (B) were harvested, and homogenates were plated on SS 
agar plates. (c,D) BALB/c mice were orally immunized on days 0 and 7 with 
HKS alone, buffer, or U-Omp19 alone. Fourteen days post-last immunization, 
mice were orally infected with S. Typhimurium. Six days postinfection mice 
were sacrificed, spleen (c) and liver (D) were harvested, and homogenates 
were plated on SS agar plates. CFU were counted after overnight incubation 
at 37°C. Individual mice are shown as scatter dots (*p < 0.05 vs HKS; 
ANOVA plus Bonferroni’s multiple comparisons test).
FigUre 2 | continued 
U-Omp19 increases systemic and mucosal cellular immune response against hKs. (a) BALB/c mice were orally immunized on days 0 and 7 with buffer, 
HKS alone, or HKS + U-Omp19. Fourteen days post-last immunization, mice received an intradermal injection of HKS on one footpad and saline on the 
contralateral footpad. Swelling of each footpad was measured with a caliper 72 h later, and the difference between saline and HKS injected footpad was analyzed 
(**p < 0.01; ANOVA plus Bonferroni’s multiple comparisons test). (B) BALB/c mice were orally immunized on days 0 and 7 with HKS alone, HKS + U-Omp19, or 
HKS + CT. Spleens were obtained 14 days post-last immunization, and cells’ suspensions were cultured in the presence of 0.5 μg/ml of HKS or complete medium. 
Supernatants were collected after 3 days, and cytokine production was determined by ELISA. Results from individual mice are shown as scatter dots (*p < 0.05, 
***p < 0.001 vs HKS; Kruskall–Wallis plus Dunn’s multiple comparisons test). (c) BALB/c mice were orally immunized on days 0 and 7 with HKS alone or 
HKS + U-Omp19. MLNs were obtained 14 days post-last immunization and, cells’ suspensions were cultured in the presence of 0.5 or 10 µg/ml of HKS or 
complete medium. Supernatants were collected after 3 days, and cytokine production was determined by ELISA (*p < 0.05; Kruskal–Wallis plus Dunn’s multiple 
comparisons test).
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S. Typhimurium. Animals that received HKS + U-Omp19 pre-
sented a significant reduction in bacterial burden in spleen and 
liver compared to those that were administered with HKS alone 
(Figures 3A,B), indicating that addition of U-Omp19 to the HKS 
extract can increase protection against oral S. Typhimurium chal-
lenge. In contrast, animals immunized with HKS + CTB were not 
protected against infection. Importantly, U-Omp19 orally deliv-
ered alone did not induce reduction in bacterial burden when 
compared with buffer or HKS delivered mice (Figures 3C,D).
U-Omp19 Maintains its adjuvant capacity 
in a chronic Outbred Mouse Model
Though outbred animals may cause more variability in the experi-
ments, they are more akin to the human population. Therefore, 
U-Omp19’s adjuvant capacity in the CF-1 outbred mice strain was 
evaluated. Unlike BALB/c mice, CF-1 mice present a functional 
Nramp1 gene, they are notably less susceptible to Salmonella infec-
tion, and develop a chronic disease (30), which allows protection 
studies to be performed at longer time periods. Coadministration 
of U-Omp19 was able to enhance the protective capacity of HKS 
in this mouse strain, evidenced by a reduction in fecal shedding 
of bacteria and significantly lower CFU counts in liver compared 
to HKS alone. Immunization with HKS + CT had no effect on 
fecal shedding but produced a significant reduction in bacterial 
burden at the liver (Figure 4).
U-Omp19 When coadministered with 
recombinant Salmonella Proteins 
reduces Bacterial Burden after 
Salmonella infection
Subunit vaccination is an extremely safe method of immuniza-
tion, it can be used on virtually everyone in need of vaccination 
regardless of health status and for that reason we sought to assess 
U-Omp19’s adjuvant capability using recombinant Salmonella 
antigens. We chose two antigens that have previously been 
reported to reduce CFU count after infection: SseB, a part of 
the Salmonella Pathogenicity Island II, and Flagellin, which is 
the major structural protein of Salmonella flagellum (26–28). 
Preliminary studies showed that combination of these two anti-
gens increases protective efficacy (S. J. McSorley, personal com-
munication). Since U-Omp19 proved to have adjuvant properties 
when coadministered with recombinant protein antigens orally 
as well as systemic (21, 22), both routes were evaluated. In the 
systemic (i.v.) immunization protocol, U-Omp19 was as efficient 
as control adjuvant MPLA in reducing CFU counts after infection 
at spleen and liver of immunized mice compared to naive mice. 
Of note, in the oral immunization protocol, MPLA adjuvant was 
unable to induce protection against bacterial challenge, whereas 
mice immunized with U-Omp19 presented significantly lower 
bacterial burden at the liver (Figure 5).
DiscUssiOn
Although most vaccines currently licensed are administered by 
systemic route, parenteral vaccination strategies fail to generate an 
adequate local mucosal immune response against still prevailing 
FigUre 4 | coadministration of U-Omp19 with hKs effectively reduces bacterial colonization in outbred mice after infection with Salmonella. CF-1 
mice were orally immunized on days 0 and 7 with HKS alone, HKS + U-Omp19, or HKS + CT. Twenty-one days post-last immunization, mice were orally infected 
with Salmonella Typhimurium. (a) Four weeks postinfection, fecal pellets were suspended in PBS and plated on SS agar plates. For organ colonization experiments, 
40 days postinfection mice were sacrificed, spleen (B) and liver (c) were harvested, and homogenates were plated on SS agar plates. CFU were counted after 
overnight incubation at 37°C. Individual mice are shown as scatter dots (*p < 0.05, **p < 0.01; Kruskal–Wallis plus Dunn’s multiple comparisons test).
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intestinal infections. On the contrary, oral immunization is capable 
of generating strong protective immunity at the intestinal mucosa 
as well as systemic (1–5). Particularly in developing countries, 
oral vaccination may offer a means to deal with safety concerns 
(associated with needle use) and the need for mass vaccination. 
However, in order to elicit an appropriate immune response, 
antigen digestion by proteases at the gastrointestinal tract must be 
avoided. Previous studies have shown that U-Omp19 has inhibi-
tory activity over several proteases, in particular Pepsin present 
at the stomach (21). These results explain the observed protection 
of the HKS representative antigen flagellin from proteases present 
in a mouse stomach extract. As proteases at the stomach are con-
stantly renewed, the effect of U-Omp19 consists in a delay of the 
HKS extract degradation increasing its half-life. Using chicken 
OVA as a model antigen, it was demonstrated that this delay in 
antigen degradation increases the amount of antigen that reaches 
mucosal inductive sites (21). This may also be the case in the 
HKS model contributing to the induction of a stronger immune 
response against this antigen. Of note, study of other protease 
inhibitors has shown that the protease inhibitory activity by itself 
does not induce immune response against the coadministered 
antigen; it is the combination of U-Omp19’s immunostimula-
tory properties together with a delay in antigen degradation that 
explain the adjuvant properties of U-Omp19 (21, 23).
The role of IgA in resistance against Salmonella infection is 
still controversial. Some state that antibodies against LPS, one of 
the components in the HKS extract, are associated to protection 
by blocking adhesion of bacteria to epithelial cells (39, 40), others 
declare that IgA is not required for protection since IgA-deficient 
mice can be fully protected from infection (28), while others 
propose that the primary role of B cells in acquired immunity to 
Salmonella is via the development of protective T cell immunity 
(44), so the IgA increment would not be important per  se but 
merely an immune correlate of B cell activation. In this work we 
demonstrated that after one oral boost, U-Omp19 can increase 
the amount of HKS-specific IgA in feces. Therefore, a role of this 
antibody increment in increased protection could be plausible. 
Also, coadministration of U-Omp19 did not induce a mucosal 
antibody response against itself, meaning that there would be no 
reduction of the adjuvant effect in a potential subsequent oral 
administration.
Cellular immune response has also been reported to be 
important for protection against Salmonella (41). Th1 cytokines 
and IFN-γ in particular seem to be crucial during the initial 
stages of Salmonella growth since IFN-γ−/− mice develop high 
bacterial burden and succumb rapidly to infection (42). IL-17 as 
well has been implicated in the suppression of intestinal invasion 
by Salmonella (43). In previous work we described the role of 
U-Omp19 as self-adjuvant and adjuvant of model antigens (OVA) 
capable of shifting the immune response toward a Th1–Th17 
profile (20, 21). In this work we provide additional evidence that 
supports the role of U-Omp19 as a Th1–Th17 oral adjuvant using 
antigens from a real pathogen. U-Omp19 was capable of inducing 
cell-mediated immune response in a DTH assay while increasing 
IFN-γ and IL-17 production in splenocytes from immunized 
mice, which is consistent with a strong induction of a systemic 
immune response upon oral immunization with U-Omp19 as 
adjuvant. In these experiments, CT was able to induce an increase 
in IL-17 production, as previously reported in cell culture and 
mucosal immunization models for this adjuvant (45–47).
The mucosa is the front line of host defense against most 
pathogens. Therefore, induction of local immune response is 
essential to enhance the mucosal immune barrier that prevents 
infection by enteric pathogens (48). Our findings reveal that 
U-Omp19 is capable of inducing increased levels of IFN-γ and 
IL-17 at the MLNs, indicating the triggering of local immune 
response. These results are in accordance with previous findings 
using OVA as model antigen (21).
Moreover, the overall effect of coadministration of U-Omp19 
with the antigens from HKS on antibody and cellular immune 
responses resulted in an increase in protection against challenge 
with a lethal dose of virulent S. Typhimurium in both inbred 
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BALB/c mice and outbred CF-1 mice. This proves that U-Omp19 
is effective in different genetic backgrounds despite their intrinsic 
variability. Since U-Omp19 had no effect per  se on protection 
against infection, the protective efficacy of the vaccine can only 
be attributed to U-Omp19’s adjuvant effect when coadministered 
with the antigen. Overall the adjuvant capacity of U-Omp19 on 
inducing protection against Salmonella infection was superior to 
CTB in BALB/c and similar to CT in CF-1 mice. As CT cannot be 
administered orally to humans because of its enterotoxic effects, 
our results open new options in the progress of oral-killed vaccine 
formulations against Salmonella.
In addition to circumventing safety concerns, subunit vaccines 
present further advantages to inactivated vaccines: since their 
exact composition is known, they can be more reproducible, and 
also there is no need to manipulate the virulent microorganism 
during vaccine manufacture. For sure the future of vaccinology 
is headed toward subunit vaccine production. In this work we 
were able to demonstrate that U-Omp19 is a suitable adjuvant 
in subunit vaccine formulations. Coadministration of U-Omp19 
with recombinant Salmonella antigens intravenously was capable 
of reducing bacterial burden at spleen and liver after infection. 
Remarkably, U-Omp19 worked slightly better than MPLA, 
FigUre 5 | U-Omp19 coadministered with recombinant Salmonella proteins reduces bacterial burden after Salmonella Typhimurium infection. 
BALB/c mice were immunized i.v. (a,B) or orally (c,D) on days 0 and 30 with buffer, SseB + Flagellin + U-Omp19, or SseB + Flagellin + MPLA. Thirty days 
post-last immunization, mice were i.v. (tail vein) infected with virulent S. Typhimurium. Four days later, spleen (a,c) and liver (B,D) were obtained, and bacterial load 
was determined by homogenization, serial dilution, and plating on MacConkey agar plates (*p < 0.05, ***p < 0.001; ANOVA plus Bonferroni’s multiple 
comparisons test).
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